Skip to Main Content

INFORMATION FOR

Gloria Huang, MD, FACOG

Associate Professor of Obstetrics, Gynecology & Reproductive Sciences

Extensive Research Description

Endometriosis-associated ovarian cancer

Coauthors

Research Interests

Genital Neoplasms, Female; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Ovarian Neoplasms; Pelvic Neoplasms; Uterine Neoplasms; Endometrial Neoplasms; Genomics

Selected Publications

  • Trastuzumab deruxtecan (DS-8201a), a HER2-Targeting Antibody-Drug Conjugate with Topoisomerase I Inhibitor Payload, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/neu Expression (046)Mauricio D, Bellone S, Manavella D, Harold J, Buza N, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-Targeting Antibody-Drug Conjugate with Topoisomerase I Inhibitor Payload, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/neu Expression (046) Gynecologic Oncology 2022, 166: s31-s32. DOI: 10.1016/s0090-8258(22)01265-3.
  • ARID1A deficiency as a biomarker for sensitivity to radiation and ATR inhibition (232)Li J, Li Z, Soble W, Baro M, Lee H, Damast S, Contessa J, Huang G. ARID1A deficiency as a biomarker for sensitivity to radiation and ATR inhibition (232) Gynecologic Oncology 2022, 166: s128. DOI: 10.1016/s0090-8258(22)01456-1.
  • Two-Port Robotic Laparoscopic HysterectomyMauricio D, Webster E, Harold J, Altwerger G, Azodi M, Clark M, Huang G, Menderes G, Ratner E, Santin A, Schwartz P, Andikyan V. Two-Port Robotic Laparoscopic Hysterectomy Journal Of Minimally Invasive Gynecology 2021, 28: s155. DOI: 10.1016/j.jmig.2021.09.315.
  • Prognostic Impact of Mismatch Repair Deficiency in High- and Low-Intermediate Risk, Early-Stage Endometrial Cancer Following Vaginal BrachytherapyLi J, Park H, Huang G, Young M, Ratner E, Santin A, Damast S. Prognostic Impact of Mismatch Repair Deficiency in High- and Low-Intermediate Risk, Early-Stage Endometrial Cancer Following Vaginal Brachytherapy International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s138. DOI: 10.1016/j.ijrobp.2021.07.311.
  • Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancerRoque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer Gynecologic Oncology 2021, 162: s58. DOI: 10.1016/s0090-8258(21)00753-8.
  • Charlson Comorbidity Index as a predictor of postoperative complication in octogenarians and nonagenarians with stage I endometrioid endometrial cancer: a single-institution retrospective reviewWebster E, Arkfeld C, Chang Y, Yadav G, Zeybek B, Tymon-Rosario J, Harold J, Clark M, Andikyan V, Huang G, Menderes G, Azodi M, Santin A, Schwartz P, Ratner E, Altwerger G. Charlson Comorbidity Index as a predictor of postoperative complication in octogenarians and nonagenarians with stage I endometrioid endometrial cancer: a single-institution retrospective review Gynecologic Oncology 2021, 162: s108. DOI: 10.1016/s0090-8258(21)00848-9.
  • Financial toxicity in patients with gynecologic malignanciesZeybek B, Webster E, Pogosian N, Tymon-Rosario J, Mauricio D, Harold J, Menderes G, Altwerger G, Malette J, Luther M, Baker L, Balch A, Clark M, Huang G, Azodi M, Ratner E, Schwartz P, Santin A, Andikyan V. Financial toxicity in patients with gynecologic malignancies Gynecologic Oncology 2021, 162: s162. DOI: 10.1016/s0090-8258(21)00950-1.
  • In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinomaTymon-Rosario J, Bonazzoli E, Guglielmi A, Bellone S, Nagarkatti N, Zammataro L, Zeybek B, Harold J, Mauricio D, Clark M, Andikyan V, Huang G, Altwerger G, Menderes G, Azodi M, Ratner E, Schwartz P, Santin A. In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma Gynecologic Oncology 2021, 162: s186-s187. DOI: 10.1016/s0090-8258(21)01001-5.
  • High-risk Endometrial Cancer: The Present and Future of Adjuvant TherapySoble W, Tymon-Rosario J, Huang G. High-risk Endometrial Cancer: The Present and Future of Adjuvant Therapy Oncology & Haematology 2021, 17: 23. DOI: 10.17925/ohr.2021.17.1.23.
  • Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab-govitecanZeybek B, Manzano A, Bianchi A, Bonazzoli E, Bellone S, Buza N, Hui P, Lopez S, Perrone E, Manara P, Zammataro L, Altwerger G, Han C, Tymon-Rosario J, Menderes G, Ratner E, Silasi D, Huang G, Azodi M, Schwartz P, Santin A. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab-govitecan Gynecologic Oncology 2020, 159: 177. DOI: 10.1016/j.ygyno.2020.05.265.
  • Patient experience with medical marijuana in women with gynecologic malignancies: A single-institution survey-based studyWebster E, Yadav G, Gysler S, McNamara B, Black J, Tymon-Rosario J, Zeybek B, Han C, Menderes G, Huang G, Silasi D, Azodi M, Schwartz P, Santin A, Ratner E, Altwerger G. Patient experience with medical marijuana in women with gynecologic malignancies: A single-institution survey-based study Gynecologic Oncology 2020, 159: 318. DOI: 10.1016/j.ygyno.2020.05.575.
  • The PARP inhibitor niraparib demonstrates preclinical activity against HRD-deficient carcinosarcomasTymon-Rosario J, Manara P, Manzano A, Zammataro L, Bonazzoli E, Perrone E, Bellone S, Alexandrov L, Zeybek B, Han C, Altwerger G, Menderes G, Ratner E, Silasi D, Huang G, Azodi M, Schwartz P, Santin A. The PARP inhibitor niraparib demonstrates preclinical activity against HRD-deficient carcinosarcomas Gynecologic Oncology 2020, 159: 255. DOI: 10.1016/j.ygyno.2020.05.438.
  • Chemotherapy choice and impact on survival of patients with carcinosarcoma of the ovary: A retrospective reviewHosier H, Haunschild C, Altwerger G, Webster E, Buza N, Tymon-Rosario J, Zeybek B, Han C, Menderes G, Huang G, Silasi D, Azodi M, Schwartz P, Santin A, Ratner E, English D. Chemotherapy choice and impact on survival of patients with carcinosarcoma of the ovary: A retrospective review Gynecologic Oncology 2020, 159: 124-125. DOI: 10.1016/j.ygyno.2020.05.150.
  • Abstract 4851: Combination of letrozole plus abemaciclib is synergistic and suppresses tumor growth in ovarian and endometrial cancer modelsOsagie O, Li Z, Jing J, Huang G. Abstract 4851: Combination of letrozole plus abemaciclib is synergistic and suppresses tumor growth in ovarian and endometrial cancer models Cancer Research 2020, 80: 4851-4851. DOI: 10.1158/1538-7445.am2020-4851.
  • Endometrial Cancer Risk Prediction and Stratification Using Personal Health DataHart G, Nartowt B, Muhammad W, Liang Y, Huang G, Deng J. Endometrial Cancer Risk Prediction and Stratification Using Personal Health Data International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e134-e135. DOI: 10.1016/j.ijrobp.2019.06.2170.
  • Stage III Uterine Serous Carcinoma: Improved Outcomes in the Modern Era with Multi-Modality TreatmentLi J, Young M, Huang G, Litkouhi B, Santin A, Schwartz P, Damast S. Stage III Uterine Serous Carcinoma: Improved Outcomes in the Modern Era with Multi-Modality Treatment International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s225. DOI: 10.1016/j.ijrobp.2019.06.318.
  • Sacituzumab govitecan (IMMU-132) in uterine serous carcinomaHan C, Bianchi A, Bellone S, Altwerger G, Menderes G, Zeybek B, Haines K, Lopez S, Azodi M, Litkouhi B, Silasi D, Huang G, Ratner E, Schwartz P, Santin A. Sacituzumab govitecan (IMMU-132) in uterine serous carcinoma Gynecologic Oncology 2019, 154: 64. DOI: 10.1016/j.ygyno.2019.04.152.
  • Primary cytoreductive surgery versus neoadjuvant chemotherapy for advanced-stage uterine malignanciesAltwerger G, Haines K, Yadav G, McNamara B, Hosier H, Menderes G, Huang G, Azodi M, Silasi D, Santin A, Ratner E, Schwartz P, Litkouhi B. Primary cytoreductive surgery versus neoadjuvant chemotherapy for advanced-stage uterine malignancies Gynecologic Oncology 2019, 154: 243. DOI: 10.1016/j.ygyno.2019.04.561.
  • The combination of olaparib (Poly ADP-ribose polymerase inhibitor) with neratinib (pan-HER inhibitor) is synergistic in epithelial ovarian carcinoma overexpressing HER2.Han C, Altwerger G, Menderes G, Bellone S, Bianchi A, Yadav G, Lopez S, Manzano A, Ratner E, Azodi M, Litkouhi B, Silasi D, Huang G, Schwartz P, Santin A. The combination of olaparib (Poly ADP-ribose polymerase inhibitor) with neratinib (pan-HER inhibitor) is synergistic in epithelial ovarian carcinoma overexpressing HER2. Gynecologic Oncology 2019, 154: 35. DOI: 10.1016/j.ygyno.2019.04.084.
  • Impact of carboplatin hypersensitivity and desensitization on overall survival in patients with recurrent ovarian cancerAltwerger G, Han C, Zeybek B, Haines K, Gressel G, Huang G, Litkouhi B, Azodi M, Silasi D, Santin A, Schwartz P, Ratner E. Impact of carboplatin hypersensitivity and desensitization on overall survival in patients with recurrent ovarian cancer Gynecologic Oncology 2019, 154: 28-29. DOI: 10.1016/j.ygyno.2019.04.069.
  • Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 trial.Huang G, Merritt M, Hutson A, Strickler H, Einstein M, Brouwer-Visser J, Ramirez N, Lankes H, El-Bahrawy M, Xue X, Yu H, Mannel R, O'Malley D, Mutch D, Disilvestro P, Geller M, Guntupalli S, Birrer M, Miller D, Gunter M. Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 trial. Journal Of Clinical Oncology 2019, 37: 5509-5509. DOI: 10.1200/jco.2019.37.15_suppl.5509.
  • ARID1A interacts with nonmuscle myosin IIA to regulate cancer cell motility.Osagie O, Li Z, Mi S, Aguilan J, Huang G. ARID1A interacts with nonmuscle myosin IIA to regulate cancer cell motility. Journal Of Clinical Oncology 2019, 37: e17036-e17036. DOI: 10.1200/jco.2019.37.15_suppl.e17036.
  • Remarkable in vitro and in vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to the tubulin-disrupting maytansinoid DM4, in biologically aggressive (type II) endometrial cancersAltwerger G, Bonazzoli E, Bellone S, Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte J, Buza N, Hui P, Litkouhi B, Ratner E, Silasi D, Huang G, Azodi M, Schwartz P, Santin A. Remarkable in vitro and in vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to the tubulin-disrupting maytansinoid DM4, in biologically aggressive (type II) endometrial cancers Gynecologic Oncology 2018, 149: 70. DOI: 10.1016/j.ygyno.2018.04.159.
  • Assessment of BRCA testing uptake in ovarian cancer patients during the implementation of an oncologist-led genetic counseling model at an urban and suburban teaching hospital.Jorgensen J, Chiu K, Gotimer K, Chalas E, Kuo D, Huang G. Assessment of BRCA testing uptake in ovarian cancer patients during the implementation of an oncologist-led genetic counseling model at an urban and suburban teaching hospital. Journal Of Clinical Oncology 2017, 35: 1589-1589. DOI: 10.1200/jco.2017.35.15_suppl.1589.
  • ENGAGE: Evaluation of a streamlined oncologist-led BRCA mutation ( BRCA m) testing and counselling model for patients with ovarian cancer.Colombo N, Scambia G, Chalas E, Huang G, Pignata S, Fiorica J, Van Le L, Ghamande S, Gonzalez Santiago S, Bover I, Suárez B, Green A, Huot-Marchand P, Bourhis Y, Karve S, Blakeley C. ENGAGE: Evaluation of a streamlined oncologist-led BRCA mutation ( BRCA m) testing and counselling model for patients with ovarian cancer. Journal Of Clinical Oncology 2017, 35: 5559-5559. DOI: 10.1200/jco.2017.35.15_suppl.5559.
  • LBA34 A novel oncologist-led BRCA1/2 germline mutation (gBRCAm) testing and counselling model for patients with ovarian cancer: Interim results from the ENGAGE (NCT02406235) studyScambia G, Chalas E, Huang G, Suárez B, González-Santiago S, Colombo N, Pignata S, Huot-Marchand P, Karve S, Blakeley C. LBA34 A novel oncologist-led BRCA1/2 germline mutation (gBRCAm) testing and counselling model for patients with ovarian cancer: Interim results from the ENGAGE (NCT02406235) study Annals Of Oncology 2016, 27: vi569. DOI: 10.1093/annonc/mdw435.28.
  • Endometrial expression of hormonal and insulin/IGF receptors in relation to cancer risk factorsMerritt M, Strickler H, Einstein M, Cossio M, Whitney K, Gunter M, Huang G. Endometrial expression of hormonal and insulin/IGF receptors in relation to cancer risk factors Gynecologic Oncology 2016, 141: 172-173. DOI: 10.1016/j.ygyno.2016.04.449.
  • Evaluating a novel oncologist-led BRCA1/2 mutation ( BRCA m) testing counseling model for patients with ovarian cancer: Interim results from the ENGAGE study.Huang G, Tchakov I, Bourhis Y, Scambia G, Capoluongo E, Grana-Suarez B, Lopez-Guerrero J, Poveda A, Karve S, Potter D, Lawrence D, Tyczynski J, Chalas E. Evaluating a novel oncologist-led BRCA1/2 mutation ( BRCA m) testing counseling model for patients with ovarian cancer: Interim results from the ENGAGE study. Journal Of Clinical Oncology 2016, 34: e17048-e17048. DOI: 10.1200/jco.2016.34.15_suppl.e17048.
  • Evaluation of circulating neutrophils as a biomarker for outcomes in uterine carcinosarcoma.Van Arsdale A, Arend R, Mitchell C, Gilbert A, Leath C, Huang G. Evaluation of circulating neutrophils as a biomarker for outcomes in uterine carcinosarcoma. Journal Of Clinical Oncology 2016, 34: e17121-e17121. DOI: 10.1200/jco.2016.34.15_suppl.e17121.
  • Abstract 5131: Establishment of uterine carcinosarcoma primary cell lines for chemosensitivity testing and evaluation of targeted therapyBrouwer-Visser J, Scott E, Mi S, Cossio M, Hebert T, Huang G. Abstract 5131: Establishment of uterine carcinosarcoma primary cell lines for chemosensitivity testing and evaluation of targeted therapy 2015, 5131-5131. DOI: 10.1158/1538-7445.am2015-5131.
  • Abstract 5257: Immunohistochemical analysis and comprehensive hormone receptor profiling of uterine adenosarcomas at a single institutionZechmeister J, Huang G, Karabakhtsian R, Schwartz M, Prossnitz E, Goldberg G, Klobocista M. Abstract 5257: Immunohistochemical analysis and comprehensive hormone receptor profiling of uterine adenosarcomas at a single institution 2015, 5257-5257. DOI: 10.1158/1538-7445.am2015-5257.
  • Evaluation of a novel combination treatment strategy using patient-derived xenografts of uterine carcinosarcomaBrouwer-Visser J, Mi S, Cossio M, Schwartz M, Hebert T, Zou Y, Kuo D, Huang G. Evaluation of a novel combination treatment strategy using patient-derived xenografts of uterine carcinosarcoma Gynecologic Oncology 2015, 137: 201-202. DOI: 10.1016/j.ygyno.2015.01.506.
  • Evaluation of insulin-like growth factor 2 as a biomarker in uterine carcinosarcomaCossio M, Arend R, Van Arsdale A, Erickson B, Wang Y, Doo D, Leath C, Goldberg G, Huang G. Evaluation of insulin-like growth factor 2 as a biomarker in uterine carcinosarcoma Gynecologic Oncology 2015, 137: 60-61. DOI: 10.1016/j.ygyno.2015.01.141.
  • Subcellular localization and function of insulin-like growth factor 2 (IGF2) in uterine carcinosarcomaHeim J, Mi S, Cossio-Poblete M, Brouwer-Visser J, Wang Y, Gunter M, Huang G. Subcellular localization and function of insulin-like growth factor 2 (IGF2) in uterine carcinosarcoma Gynecologic Oncology 2014, 133: 111. DOI: 10.1016/j.ygyno.2014.03.295.
  • Expression of GPER, ERβ, ERα, and PR in gynecologic sarcomasKlobocista M, Phaeton R, Burton E, Van Arsdale A, Hebert T, Smith H, Arias-Pulido H, Prossnitz E, Goldberg G, Huang G. Expression of GPER, ERβ, ERα, and PR in gynecologic sarcomas Gynecologic Oncology 2014, 133: 114. DOI: 10.1016/j.ygyno.2014.03.301.
  • ER-alpha, PR, EGFR and GPER expression differentially correlate with survival in endometrial carcinomaSmith H, Qualls C, Huang G, Arias-Pulido H, Howard T, Joste N, Van Arsdale A, Prossnitz E. ER-alpha, PR, EGFR and GPER expression differentially correlate with survival in endometrial carcinoma Gynecologic Oncology 2013, 130: e86. DOI: 10.1016/j.ygyno.2013.04.260.
  • Predictors and incidence of radical vulvectomy complications in the modern era: A National Surgical Quality Improvement Program studyLin J, Yu M, Beriwal S, Krivak T, Huang G, Sukumvanich P. Predictors and incidence of radical vulvectomy complications in the modern era: A National Surgical Quality Improvement Program study Gynecologic Oncology 2013, 130: e38. DOI: 10.1016/j.ygyno.2013.04.148.
  • RACGAP1 overexpression in uterine carcinosarcomas.Mi S, Lin M, Heim J, Isani S, Brouwer-Visser J, Cossio-Poblete M, Smotkin D, Gunter M, Zheng D, Huang G. RACGAP1 overexpression in uterine carcinosarcomas. Journal Of Clinical Oncology 2013, 31: e22009-e22009. DOI: 10.1200/jco.2013.31.15_suppl.e22009.
  • Abstract 948: In vivo evaluation of IGF2 RNA interference in a mouse xenograft model of paclitaxel-resistant human ovarian cancer.Brouwer-Visser J, Lee J, Cossio M, Huang G. Abstract 948: In vivo evaluation of IGF2 RNA interference in a mouse xenograft model of paclitaxel-resistant human ovarian cancer. Cancer Research 2013, 73: 948-948. DOI: 10.1158/1538-7445.am2013-948.
  • Abstract 1080: Effect of IGF2 overexpression on the tumorigenicity of human ovarian carcinoma cellsBrouwer-Visser J, Cossio M, Chao S, Huang G. Abstract 1080: Effect of IGF2 overexpression on the tumorigenicity of human ovarian carcinoma cells Cancer Research 2012, 72: 1080-1080. DOI: 10.1158/1538-7445.am2012-1080.
  • Modulation of drug resistance in ovarian carcinoma cells by insulin-like growth factor-2 RNA interferenceBrouwer-Visser J, Lee J, Huang G. Modulation of drug resistance in ovarian carcinoma cells by insulin-like growth factor-2 RNA interference Gynecologic Oncology 2012, 125: s135. DOI: 10.1016/j.ygyno.2011.12.330.
  • Abstract A48: Effect of constitutive IGF2 overexpression on tumorigenicity of human ovarian carcinoma cellsBrouwer-Visser J, Chao S, Huang G. Abstract A48: Effect of constitutive IGF2 overexpression on tumorigenicity of human ovarian carcinoma cells Cancer Research 2011, 71: a48-a48. DOI: 10.1158/1538-7445.fbcr11-a48.
  • Tumor expression of the type I insulin-like growth factor receptor is an independent prognostic factor in epithelial ovarian cancerHuang G, Hebert T, Kim C, Lin J, Arias-Pulido H, Smith H. Tumor expression of the type I insulin-like growth factor receptor is an independent prognostic factor in epithelial ovarian cancer Gynecologic Oncology 2011, 120: s58. DOI: 10.1016/j.ygyno.2010.12.140.
  • Antiproliferative activity of a phenolic extract from a native Chilean Amaranthaceae plant in drug-resistant ovarian cancer cell linesBrouwer-Visser J, Cossio M, Urzùa N, Montenegro G, Horwitz S, Moreno R, Huang G. Antiproliferative activity of a phenolic extract from a native Chilean Amaranthaceae plant in drug-resistant ovarian cancer cell lines Gynecologic Oncology 2011, 120: s43. DOI: 10.1016/j.ygyno.2010.12.106.
  • Abstract 1809: Reversal of Taxol resistance in ovarian cancer cell lines by IGF pathway inhibitionBrouwer-Visser J, Horwitz S, Huang G. Abstract 1809: Reversal of Taxol resistance in ovarian cancer cell lines by IGF pathway inhibition Cancer Research 2010, 70: 1809-1809. DOI: 10.1158/1538-7445.am10-1809.
  • Abstract A33: in ovarian cancer cell lines resistant to microtubule-stabilizing agents, expression of IGF2 and ABCB1 is increased and IGF1R inhibition restores drug sensitivityBrouwer-Visser J, Horwitz S, Huang G. Abstract A33: in ovarian cancer cell lines resistant to microtubule-stabilizing agents, expression of IGF2 and ABCB1 is increased and IGF1R inhibition restores drug sensitivity Clinical Cancer Research 2010, 16: a33-a33. DOI: 10.1158/1078-0432.tcme10-a33.
  • Consolidation therapy for ovarian cancerHuang G, Goldberg G, Fields A. Consolidation therapy for ovarian cancer The Women's Oncology Review 2005, 5: 3-8. DOI: 10.3109/14733400500070708.
  • Consolidation therapy for ovarian cancerHuang G, Goldberg G, Fields A. Consolidation therapy for ovarian cancer The Women's Oncology Review 2005, 5: 3-8. DOI: 10.1080/14733400500070708.
  • Total Laparoscopic HysterectomyO'Hanlan K, Lopez L, Dibble S, Garnier A, Huang G, Leuchtenberger M. Total Laparoscopic Hysterectomy Obstetrics And Gynecology 2003, 102: 1384-1392. DOI: 10.1097/00006250-200312000-00028.

Clinical Trials